Precision Biosciences logo

Precision Biosciences Share Price Today

(NASDAQ: DTIL)

Precision Biosciences share price is $5.01 & ₹432.43 as on 20 Mar 2025, 2.30 'hrs' IST

$5.01

0.03

(0.6%)

Market is closed - opens 7 PM, 20 Mar 2025

View live Precision Biosciences share price in Dollar and Rupees. Guide to invest in Precision Biosciences stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Precision Biosciences, along with analyst recommendations, forecasts, and comprehensive financials.

Precision Biosciences share price movements

  • Today's Low: $4.85
    Today's High: $5.02

    Day's Volatility :3.37%

  • 52 Weeks Low: $3.61
    52 Weeks High: $15.97

    52 Weeks Volatility :77.4%

Precision Biosciences (DTIL) Returns

PeriodPrecision Biosciences IncSector (Health Care)Index (Russel 2000)
3 Months
8.26%
7.7%
0.0%
6 Months
-47.41%
-5.8%
0.0%
1 Year
-59.28%
0.7%
0.0%
3 Years
-94.56%
7.2%
-15.2%

Precision Biosciences (DTIL) Key Statistics

in dollars & INR

Previous Close
$4.98
Open
$4.95
Today's High
$5.02
Today's Low
$4.8506
Market Capitalization
$38.7M
Today's Volume
$59.6K
52 Week High
$15.97
52 Week Low
$3.61
Revenue TTM
$75.1M
EBITDA
$-12.0M
Earnings Per Share (EPS)
$0.4
PE Ratio
12.45
Profit Margin
11.48%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
24.44%

How to invest in Precision Biosciences Stock (DTIL) from India?

It is very easy for Indian residents to invest directly in Precision Biosciences from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Precision Biosciences stock in both Indian Rupees (INR) and US Dollars (USD). Search for Precision Biosciences or DTIL on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Precision Biosciences or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Precision Biosciences shares which would translate to 0.172 fractional shares of Precision Biosciences as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Precision Biosciences, in just a few clicks!

Returns in Precision Biosciences (DTIL) for Indian investors in Rupees

The Precision Biosciences stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Precision Biosciences investment value today

Current value as on today

₹44,982

Returns

₹55,018

(-55.02%)

Returns from Precision Biosciences Stock

₹59,035 (-59.04%)

Dollar Returns

₹4,018 (+4.02%)

Indian investors sentiment towards Precision Biosciences (DTIL)

145%

Period: Feb 17, 2025 to Mar 19, 2025. Change in 30 Days versus previous period

Search interest for Precision Biosciences Stock from India on INDmoney has increased by 145% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Precision Biosciences

  • TANG CAPITAL MANAGEMENT LLC

    8.78%

  • Aquilo Capital Management, LLC

    6.99%

  • Goldman Sachs Group Inc

    3.94%

  • Vanguard Group Inc

    3.63%

  • Citadel Advisors Llc

    2.00%

  • Renaissance Technologies Corp

    1.43%

Analyst Recommendation on Precision Biosciences

Buy

    83%Buy

    16%Hold

    0%Sell

Based on 12 Wall street analysts offering stock ratings for Precision Biosciences(by analysts ranked 0 to 5 stars)

Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
8
8
Hold
2
2
2
Sell
0
0
0

Analyst Forecast on Precision Biosciences Stock (DTIL)

What analysts predicted

Upside of 570.66%

Target:

$33.60

Current:

$5.01

Insights on Precision Biosciences Stock (Ticker Symbol: DTIL)

  • Price Movement

    In the last 3 years, DTIL stock has moved down by -95.0%
  • Price Movement

    In the last 3 years, DTIL stock has moved down by -30.4%
  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 49.89M → 576.0K (in $), with an average decrease of 98.9% per quarter
  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 168.35 Cr → 138.97 Cr (in ₹), with an average decrease of 17.5% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 32.74M → -16.42M (in $), with an average decrease of 150.2% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 25.99 Cr → -0.96 Cr (in ₹), with an average decrease of 103.7% per quarter
  • DTIL vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 64.9% return, outperforming this stock by 123.4%
  • DTIL vs ALNY (1 yr)

    In the last 1 year, Avanti Feeds Ltd has given 85.9% return, outperforming this stock by 93.7%
  • DTIL vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.8% return, outperforming this stock by 142.8%
  • DTIL vs VRTX (3 yr)

    In the last 3 years, Avanti Feeds Ltd has given 111.0% return, outperforming this stock by 141.3%
  • Price to Sales

    ForDTIL every $1 of sales, investors are willing to pay $0.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.4 for every $1 of sales.

DTIL Precision Biosciences Financials in INR & Dollars

FY18Y/Y Change
Revenue
$10.9M
↑ 67.84%
Net Income
$-46.0M
↑ 118.16%
Net Profit Margin
-423.02%
↓ 97.57%
FY19Y/Y Change
Revenue
$22.2M
↑ 104.34%
Net Income
$-83.3M
↑ 80.94%
Net Profit Margin
-374.59%
↑ 48.43%
FY20Y/Y Change
Revenue
$24.3M
↑ 9.2%
Net Income
$-109.0M
↑ 30.86%
Net Profit Margin
-448.86%
↓ 74.27%
FY21Y/Y Change
Revenue
$115.5M
↑ 375.72%
Net Income
$-30.9M
↓ 71.64%
Net Profit Margin
-26.76%
↑ 422.1%
FY22Y/Y Change
Revenue
$25.1M
↓ 78.28%
Net Income
$-122.9M
↑ 297.53%
Net Profit Margin
-489.71%
↓ 462.95%
FY23Y/Y Change
Revenue
$48.7M
↑ 94.15%
Net Income
$-61.3M
↓ 50.11%
Net Profit Margin
-125.84%
↑ 363.87%
Q2 FY23Q/Q Change
Revenue
$19.8M
↑ 125.39%
Net Income
$-11.9M
↓ 49.52%
Net Profit Margin
-60.09%
↑ 208.22%
Q3 FY23Q/Q Change
Revenue
$13.1M
↓ 33.7%
Net Income
$-8.1M
↓ 32.06%
Net Profit Margin
-61.58%
↓ 1.49%
Q4 FY23Q/Q Change
Revenue
$7.0M
↓ 46.36%
Net Income
$-16.3M
↑ 101.62%
Net Profit Margin
-231.44%
↓ 169.86%
Q1 FY24Q/Q Change
Revenue
$17.6M
↑ 149.84%
Net Income
$8.6M
↓ 152.72%
Net Profit Margin
48.84%
↑ 280.28%
Q2 FY24Q/Q Change
Revenue
$49.9M
↑ 183.77%
Net Income
$32.7M
↑ 281.33%
Net Profit Margin
65.63%
↑ 16.79%
Q3 FY24Q/Q Change
Revenue
$576.0K
↓ 98.85%
Net Income
$-16.4M
↓ 150.15%
Net Profit Margin
-2.9K%
↓ 2917.19%
FY18Y/Y Change
Profit
$10.9M
↑ 67.84%
FY19Y/Y Change
Profit
$22.2M
↑ 104.34%
FY20Y/Y Change
Profit
$24.3M
↑ 9.2%
FY21Y/Y Change
Profit
$115.5M
↑ 375.72%
FY22Y/Y Change
Profit
$16.1M
↓ 86.07%
FY23Y/Y Change
Profit
$40.5M
↑ 151.47%
Q2 FY23Q/Q Change
Profit
$17.4M
↑ 167.67%
Q3 FY23Q/Q Change
Profit
$11.1M
↓ 36.31%
Q4 FY23Q/Q Change
Profit
$5.5M
↓ 50.54%
Q1 FY24Q/Q Change
Profit
$16.2M
↑ 194.73%
Q2 FY24Q/Q Change
Profit
$48.5M
↑ 200.28%
Q3 FY24Q/Q Change
Profit
$-435.0K
↓ 100.9%
FY18Y/Y Change
Operating Cash Flow
$-51.7M
↑ 114.01%
Investing Cash Flow
$-15.7M
↑ 184.01%
Financing Cash Flow
$107.8M
↓ 11602.35%
FY19Y/Y Change
Operating Cash Flow
$-71.0M
↑ 37.3%
Investing Cash Flow
$-24.7M
↑ 57.48%
Financing Cash Flow
$173.4M
↑ 60.86%
FY20Y/Y Change
Operating Cash Flow
$-87.4M
↑ 23.05%
Investing Cash Flow
$-5.0M
↓ 79.6%
Financing Cash Flow
$1.3M
↓ 99.23%
FY21Y/Y Change
Operating Cash Flow
$-10.9M
↓ 87.58%
Investing Cash Flow
$-5.8M
↑ 15.34%
Financing Cash Flow
$70.5M
↑ 5206.32%
FY22Y/Y Change
Operating Cash Flow
$-45.8M
↑ 321.57%
Investing Cash Flow
$-3.3M
↓ 42.81%
Financing Cash Flow
$95.0M
↑ 34.69%
Q2 FY23Q/Q Change
Operating Cash Flow
$-21.1M
↓ 32.83%
Investing Cash Flow
$-1.1M
↑ 46.46%
Financing Cash Flow
$1.9M
↑ 149.93%

Precision Biosciences Technicals Summary

Sell

Neutral

Buy

Precision Biosciences is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Precision Biosciences (DTIL) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Precision Biosciences Inc logo
-3.3%
-47.41%
-59.28%
-94.56%
-97.07%
Regeneron Pharmaceuticals, Inc. logo
-2.21%
-42.19%
-31.23%
-4.07%
45.94%
Beone Medicines Ltd logo
9.77%
31.62%
54.1%
45.52%
104.52%
Vertex Pharmaceuticals Incorporated logo
10.85%
7.18%
24.29%
104.68%
153.32%
Alnylam Pharmaceuticals, Inc. logo
-2.28%
-11.59%
65.08%
50.4%
146.62%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Precision Biosciences Inc logo
12.45
12.45
NA
1.03
0.24
-0.06
NA
8.67
Regeneron Pharmaceuticals, Inc. logo
17.7
17.7
1.0
42.64
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.45
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.43
18.06
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.52
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Precision Biosciences Inc logo
Buy
$38.7M
-97.07%
12.45
11.48%
Regeneron Pharmaceuticals, Inc. logo
Buy
$74.2B
45.94%
17.7
31.07%
Beone Medicines Ltd logo
NA
$28.4B
104.52%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$131.9B
153.32%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$32.8B
146.62%
NA
-12.37%

About Precision Biosciences

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Organization
Precision Biosciences
Employees
108
CEO
Mr. Naresh Tanna
Industry
Biotechnology

Management People of Precision Biosciences

NameTitle
Mr. Michael Amoroso
President, CEO & Director
Mr. John Alexander Kelly R.Ph.
CFO & Principal Accounting Officer
Dr. Jefferson J. Smith Ph.D.
Co-Founder & Chief Research Officer
Dr. Cassie Gorsuch Ph.D.
Chief Scientific Officer
Mr. Naresh Tanna
Chief of Staff to CEO & Head of Investor Relations
Mr. Dario Scimeca J.D.
General Counsel & Secretary
Ms. Juli Blanche
Chief People Officer
Mr. Garrett Gincley
Head of Manufacturing
Ms. Cindy Atwell
Chief Development & Business Officer
Mr. Neil Leatherbury M.S.
Senior VP and Head of Chemistry, Manufacturing & Controls

Important FAQs about investing in DTIL Stock from India :

What is Precision Biosciences share price today?

Precision Biosciences share price today stands at $5.01, Open: $4.95 ; Previous Close: $4.98 ; High: $5.02 ; Low: $4.85 ; 52 Week High: $15.97 ; 52 Week Low: $3.61.

The stock opens at $4.95, after a previous close of $4.98. The stock reached a daily high of $5.02 and a low of $4.85, with a 52-week high of $15.97 and a 52-week low of $3.61.

Can Indians buy Precision Biosciences shares?

Yes, Indians can invest in the Precision Biosciences (DTIL) from India.

With INDmoney, you can buy Precision Biosciences at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Precision Biosciences at zero transaction cost.

How can I buy Precision Biosciences shares from India?

It is very easy to buy Precision Biosciences from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Precision Biosciences (DTIL) be purchased?

Yes, you can buy fractional shares of Precision Biosciences with INDmoney app.

What are the documents required to start investing in Precision Biosciences stocks?

To start investing in Precision Biosciences, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Precision Biosciences Stock (DTIL)?

Today’s highest price of Precision Biosciences (DTIL) is $5.02.

Today’s lowest price of Precision Biosciences (DTIL) is $4.85.

What is today's market capitalisation of Precision Biosciences?

Today's market capitalisation of Precision Biosciences DTIL is 38.7M

What is the 52 Week High and Low Range of Precision Biosciences Stock (DTIL)?

  • 52 Week High

    $15.97

  • 52 Week Low

    $3.61

What are the historical returns of Precision Biosciences (DTIL)?

  • 1 Month Returns

    -3.3%

  • 3 Months Returns

    -47.41%

  • 1 Year Returns

    -59.28%

  • 5 Years Returns

    -97.07%

Who is the Chief Executive Officer (CEO) of Precision Biosciences ?

Mr. Naresh Tanna is the current Chief Executive Officer (CEO) of Precision Biosciences.